Dermatitis Drugs Market Size, Global Industry Revenue by Segments, Key Players & Regions Forecast 2026

Sep 7, 2019

Dermatitis Drugs Market Size, Share and Global Trend by Drug Class (Calcineurin Inhibitors, PDE4 Inhibitors, Corticosteroids, Biologics & Others), By Disease Indication (Atopic Dermatitis, ontact Dermatitis & Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy & Online Pharmacy), and Geography Forecast to 2026

Pune, India - September 7, 2019 /MarketersMedia/ —

The Global Dermatitis Drugs Market will expand considerably in the coming years driven by the advancements across numerous drug classes. According to a report published by Fortune Business Insights, titled “Dermatitis Drugs: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 6,097.4 Mn in 2018. Fortune Business Insights predicts that the market will rise impressively at a CAGR of 10.2% and reach US$ 13,630.8 Mn by the end of 2026.

Browse Complete Report: https://www.fortunebusinessinsights.com/industry-reports/dermatitis-drugs-market-100658

Major Leading Players Mentioned:

• Valeant Pharmaceuticals
• Astellas Pharma US
• Pfizer
• Mylan
• Bayer
• Allergan
• LEO Pharma
• Regeneron Pharmaceuticals, Inc.
• Anacor Pharmaceuticals

The severity of dermatitis has led to an increasing need for efficient drugs. This, in turn, has led to a growing emphasis on the research and development of newer drugs that can be used in compliance with the regulations, enforced by related authorities. Increasing usage approvals will open up numerous windows for the growth of the global market. The report provides an in-depth analysis of various companies that have made significant contributions to the growth of the global dermatitis drugs market.

Topical Treatment for Atopic Dermatitis gets FDA Nod, Subsequently Aiding the Market’s Expansion

The global dermatitis drugs market will derive significant growth from increasing usage approvals. In 2017, the Food and Drug Administration passed approval for a new topical treatment for atopic dermatitis. The topical treatment ‘Eucrisa’ was aimed at the treatment of children and adults with mild to moderate atopic dermatitis. The use of Eucrisa to minimize the effects of dermatitis has fueled the demand for the products, across the world. The ability of Eucrisa to act on a body enzyme ‘PDE4’ has created several benefits of the product and this, in turn, will lead to an increase in adoption. After successful clinical trials, Eucrisa was seen to reduce skin rashes, itching, and lichenification. The applications of Eucrisa in the healthcare industry have had a positive impact on the Global Dermatitis Drugs Market and will favor the growth of the market in the coming years. Fortune Business Insights has predicted that growing usage approvals will bode well for the market in the near future.

Get Exclusive Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/dermatitis-drugs-market-100658

Increasing Mergers and Acquisitions Will Enable Growth

The global atopic dermatitis market will witness growth opportunities due to contributions from leading companies and their exceptional business strategies. Recent trends in dermatitis treatment include company mergers and acquisitions, aimed at the betterment of prevailing drugs and creating new drugs. The growing mergers and acquisitions have boded well for the market and Fortune Business Insights has predicted that these activities will induce significant growth in the global dermatitis market in the coming years.
In 2016, Pfizer announced that it plans to acquire Anacor Pharmaceuticals for an estimated US$ 5.2 Bn. The company has splashed a huge amount for the take-over of Anacor and this is a strong indication of future growth. The report includes mergers and acquisition similar to the Pfizer-Anacor deal and gauges the impact of such M&As on the global dermatitis drugs market.

Major Table of Content:

1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. Prevalence of major dermatitis types by key countries, 2018
4.2. Recent industry developments such as mergers & acquisitions
4.3. Pipeline analysis
4.4. Patent landscape
4.5. Reimbursement scenario by key countries
4.6. Regulatory scenario for key countries

TOC Continued…!

Get Discount: https://www.fortunebusinessinsights.com/enquiry/check-discount/dermatitis-drugs-market-100658

View More Related Reports:

Global Blood Glucose Meters Market Size, Share, Key Players Overview and Geographical Outlook 2026

Commercial Seaweed Market Size, Share, Trade Analysis, Global Insights and Geographical Overview till 2025

Contact Info:
Name: Ashwin Arora
Email: Send Email
Organization: Fortune Business Insights Pvt Ltd
Address: Fortune Business Insights Pvt. Ltd., 308, Supreme Headquarters,, Survey No. 36, Baner,, Pune-Bangalore Highway,, Pune - 411045, Maharashtra, India., , Phone:, US :+1 424 253 0390, UK : +44 2071 939123, APAC : +91 744 740 1245, Email: [email protected]
Phone: +14242530390
Website: https://www.fortunebusinessinsights.com/industry-reports/dermatitis-drugs-market-100658

Source URL: https://marketersmedia.com/dermatitis-drugs-market-size-global-industry-revenue-by-segments-key-players-regions-forecast-2026/88916116

Source: MarketersMedia

Release ID: 88916116

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

More News

Latest inflation figures higher than expected
Oct 28, 2026
Latest inflation figures higher than expected

The latest inflation figures are higher than expected, fuelling fears of another interest rate hike.

Anthropic brings its mega IPO to Australia’s AI-starved investors
Oct 28, 2026
Anthropic brings its mega IPO to Australia’s AI-starved investors

Australia is one of a few countries around the world where mum and dad investors can directly buy into the Anthropic IPO.

Trump’s America is facing a reckoning as it drowns in debt
Oct 28, 2026
Trump’s America is facing a reckoning as it drowns in debt

The clock may be ticking on America’s “exorbitant privilege”.

Will axe fall on Shuhaily? Fate hangs on review
Oct 28, 2026
Will axe fall on Shuhaily? Fate hangs on review

Assignment at MCBA is for two years, says IGP.

Sex offender escapes government custody at PCYC
Oct 28, 2026
Sex offender escapes government custody at PCYC

The public has been urged not to approach Denzel Dynevor.

Chris Minns is right to fear a One Nation wipeout
Oct 28, 2026
Chris Minns is right to fear a One Nation wipeout

Some Labor voters are unimpressed by what they’re seeing from Macquarie Street, but could Hanson and her contrarians cut the mustard (and the ribbon)?

Mushroom killer to learn fate after appeal against triple murder conviction
Oct 28, 2026
Mushroom killer to learn fate after appeal against triple murder conviction

Mushroom killer Erin Patterson will learn this week if her appeal against her triple murder conviction is successful or if she will spend more time in prison.

Victim identified in fatal Melbourne shooting
Oct 28, 2026
Victim identified in fatal Melbourne shooting

Police have identified 55-year-old Elias Serevetas as the victim of a suspected targeted underworld hit in Reservoir.

Andy Burnham government announces huge change as 'unfair' gas charges for 23 million homes scrapped
Oct 28, 2026
Andy Burnham government announces huge change as 'unfair' gas charges for 23 million homes scrapped

John Healey is to scrap the 'unfair and outdated' charges

Court sentences Chegubard to 4 months imprisonment over criminal defamation
Oct 28, 2026
Court sentences Chegubard to 4 months imprisonment over criminal defamation

However, Sessions Court judge grants stay of execution pending appeal.

Inside WA’s first AUKUS rotation submarine – just don’t ask about the nukes
Oct 28, 2026
Inside WA’s first AUKUS rotation submarine – just don’t ask about the nukes

A US nuclear-powered submarine with 160 crew, including seven Australians, has docked south of Perth for maintenance ahead of becoming the first vessel to begin regular AUKUS rotations from WA next year.


The Upstocker

Tracks up-to-the-minute news and provides insights on financial reports, commentary, and investment data so that you can make better investment decisions.

NEWSLETTER

Copyright © 2015 - 2026 The Upstocker. All Rights Reserved.